Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials

被引：0

作者：

Rugo, H. S. ^{[1
]}

Tolaney, S. M. ^{[2
]}

Huober, J. ^{[3
]}

Toi, M. ^{[4
]}

Andre, V. ^{[5
]}

Barriga, S. ^{[6
]}

Forrester, T. ^{[7
]}

Sledge, G. W. ^{[8
]}

Goetz, M. P. ^{[9
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA

[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[3] Univ Frauenklin Ulm, Gynecol & Obstet, Ulm, Germany

[4] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan

[5] Eli Lilly & Co, Oncol, Paris, France

[6] Eli Lilly & Co, Oncol, Madrid, Spain

[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA

[8] Stanford Univ, Med Oncol, Stanford, CA 94305 USA

[9] Mayo Clin, Alliance Fdn Clin Trials Oncol, Rochester, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

339P

引用

页数：2